\
&
Contact us
\
&
Contact us
Published on | 5 years ago
ProgrammesThe launch of the full Horizon Europe programme is now very close.
Here you can find the latest version of the work programme for cluster 5 climate, energy and mobility.
This is still a draft version so minor changes to the texts are still possible.
If you want information regarding the background of these calls you can contact the PC representatives lut.bollen@vlaanderen.be (energy/climate) and hilde.vermeulen@vlaanderen.be (mobility)
You can also email the NCP’s bart.decaesemaeker@vlaio.be and pascal.verheye@vlaio.be if you would like to receive more information on the NCP services regarding Horizon Europe.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space Agro-Food, Environment
The 2nd EO 4 Soil Symposium is organised by the European Space Agency (ESA) and focusses on three thematic areas: policy and user uptake scientific and technical progress applications and use cases Topics include soil monitoring methods, soil organic carbon mapping, uncertainty assessment, data harmonisation, soil carbon certific... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
